secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001213900-23-090252
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar gets Nasdaq bid-price extension to May 2024; stock moves to Capital Market
--------------------------------------------------------------------------------

- Nasdaq granted additional 180-day period until May 20, 2024 to regain $1.00 minimum bid price.
- Common stock will transfer from Nasdaq Global Select to Nasdaq Capital Market on Nov 28, 2023.
- Company intends to cure deficiency via reverse stock split if needed before May 20, 2024.
- If compliance not regained, Nasdaq may delist NKTR; company can appeal to a Listing Qualifications panel.
- Stock continues to trade under symbol NKTR on the Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023090252/0001213900-23-090252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023090252/ea189022-8k_nektarther.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-090252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer